https://stage.merztherapeutics.com/us-new/merz-therapeutics-to-present-robust-data-on-xeomin-incobotulinumtoxina-at-toxins-2022-conference-in-new-orleans-la/ 2023-07-12T07:06:55+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-donates-100000-to-support-construction-of-new-rehabilitation-center-at-university-of-north-carolina/ 2023-07-12T07:07:29+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-to-present-key-data-on-xeomin-incobotulinumtoxina-at-toxins-2021-virtual-conference/ 2023-07-12T07:07:47+00:00 https://stage.merztherapeutics.com/us-new/fda-approves-pediatric-indication-for-xeomin-incobotulinumtoxinafor-the-treatment-of-chronic-sialorrhea/ 2023-07-12T07:07:59+00:00 https://stage.merztherapeutics.com/us-new/fda-approves-first-pediatric-indication-for-xeomin-incobotulinumtoxina-for-the-treatment-of-upper-limb-spasticity-excluding-spasticity-caused-by-cerebral-palsy/ 2023-07-12T07:08:14+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-closes-185m-asset-purchase-agreement-with-acorda-therapeutics/ 2024-07-10T19:08:37+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-appoints-leonard-paolillo-as-president-of-north-america/ 2024-07-30T17:00:40+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-north-america-earns-2023-great-place-to-work-certification/ 2024-08-06T11:40:22+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-partners-with-the-university-of-alabama-at-birmingham-to-advance-physician-training-in-rehabilitation-medicine/ 2025-10-16T11:58:13+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-launches-celebrating-the-fighters-campaign-channeling-muhammad-alis-resilience-to-empower-the-parkinsons-disease-community/ 2026-02-03T09:33:31+00:00 https://stage.merztherapeutics.com/us-new/merz-therapeutics-presents-new-research-at-world-parkinson-congress-2026-revealing-the-hidden-burden-of-off-episodes-in-parkinsons-disease/ 2026-05-27T15:44:40+00:00 https://stage.merztherapeutics.com/us-new/xeomin-approved-for-expanded-indication-in-pediatric-upper-limb-spasticity-uls-patients-with-cerebral-palsy-cp-following-fda-label-update/ 2026-06-25T15:07:59+00:00